Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN414 in Migraine Patients
NCT04744129Unknown
- Sponsor
- Dansk Hovedpinecenter
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of NNC 55-0414 in migraine (2 arms), sponsored by Dansk Hovedpinecenter. Primary endpoint: Occurrence and change of migraine attack at 2 hours. Status: unknown.
02
Drugs
NNC 55-0414
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04744129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744129.